The vast genetic complexity underlying autism spectrum disorders has created a therapeutic bottleneck—researchers have identified hundreds of autism-linked genes but struggle to translate these discoveries into effective treatments. This gap between genetic understanding and pharmacological intervention represents one of modern medicine's most pressing challenges for neurodevelopmental conditions. A comprehensive drug screening study using zebrafish models has identified several FDA-approved medications that can reverse behavioral and cellular abnormalities caused by autism-associated gene mutations. Researchers tested 520 existing drugs against zebrafish engineered to carry defects in known autism genes, measuring both behavioral responses and cellular function. Multiple compounds demonstrated the ability to restore normal swimming patterns, social behaviors, and neuronal activity in fish with autism gene variants. The identified drugs span diverse therapeutic classes, suggesting multiple biological pathways may offer intervention points for autism-related symptoms. This pharmaco-behavioral approach represents a significant methodological advance in autism research, offering a scalable platform to rapidly evaluate therapeutic candidates. Unlike traditional drug development that can take decades, repurposing existing FDA-approved medications could accelerate treatment timelines dramatically. The zebrafish model's genetic tractability and behavioral complexity make it particularly suited for this type of systematic screening. However, the translational gap between zebrafish and human neurology remains substantial. The behavioral measures in fish, while informative, capture only limited aspects of human autism's social and communication challenges. Additionally, drug metabolism and brain penetration differ significantly between species, meaning effective compounds in fish may not achieve therapeutic levels in humans. This work provides a valuable proof-of-concept for systematic drug repurposing in autism, though clinical validation will ultimately determine which findings translate to meaningful human therapies.